Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.
Alberto Augsten, PharmD, MS, BCPP, DABAT
Advertisement
Alberto Augsten, PharmD, is an adjunct professor at Nova Southeastern University and a medical expert witness known for tackling treatment-resistant depression.
Articles by Alberto Augsten, PharmD, MS, BCPP, DABAT
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5